Biomarkers of treatment response in clinical trials of novel antituberculosis agents (Q36831404)

16 August 2017

1 reference

title

Biomarkers of treatment response in clinical trials of novel antituberculosis agents (English)

1 reference

16 August 2017

0 references

Timothy D McHugh

3

0 references

Stephen H Gillespie

series ordinal

4

object named as

Stephen H Gillespie

1 reference

16 August 2017

Felicity M R Perrin

1

1 reference

PubMed ID

17524807

16 August 2017

Marc C I Lipman

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

Lancet Infectious Diseases

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

481-490

1 reference

16 August 2017

7

1 reference

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Anti-tuberculosis medication and the liver: dangers and recommendations in management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

How molecular epidemiology has changed what we know about tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A perspective on surrogate endpoints in controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The action of antituberculosis drugs in short-course chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Dormancy of Mycobacterium tuberculosis and latency of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The search for new sterilizing anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Clinical features and serum beta 2-microglobulin levels in HIV-1 positive and negative Tanzanian patients with tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

High resolution computed tomographic findings in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Radiolabelled antimicrobial peptides for infection detection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rapid effector function in CD8+ memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Activity of amoxicillin/clavulanate in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

The Hunt for the Elusive Surrogate Marker of Sterilizing Activity in Tuberculosis Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A reiterative method for calculating the early bactericidal activity of antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Rapid assessment of mycobacterial growth inside macrophages and mice, using the radiometric (BACTEC) method

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

A whole blood bactericidal assay for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Amplification of rRNA for assessment of treatment response of pulmonary tuberculosis patients during antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Predicting the outcome of therapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

TB: a partnership for the benefit of research and community.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

Basic Mechanisms of Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970112-3

7 January 2021

10.1016/S1473-3099(07)70112-3

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17524807